Aquestive Therapeutics, Inc. AQST
4.68
(0.14)
(2.90%)
as of 25 Sep
- Market cap
- $605.0M
- P/E
- 0.0×
Follow AQST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.61 | 10.12 | 15.51 | 14.24 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(55.08) | (34.37) | (81.56) | (48.87) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.73 | 8.42 | 13.40 | 11.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.41) | (9.65) | (11.39) | (10.29) | |
EV/FCF |
(10.28) | (9.55) | (11.27) | (10.19) | |
Quick Ratio |
6.54 | 3.70 | 2.92 | 5.51 | |
Current Ratio |
7.19 | 4.10 | 3.14 | 5.93 | |
Net Debt/EBITDA |
7.57 | 47.44 | 3.61 | 11.54 | |
Debt/Assets |
38.34% | 17.78% | 17.15% | 18.31% | |
Debt/Equity |
(0.90) | (0.74) | (0.82) | (7.29) | |
Asset Turnover |
0.48 | 0.41 | 0.34 | 0.32 | |
Operating CF/Net income |
0.41 | 1.84 | 0.27 | 0.82 | |
Capex/Depreciation |
(0.11) | (0.02) | (0.03) | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.67% | 29.10% | 24.56% | 35.37% | |
Selling, General and Administrative Expense of Revenue |
101.77% | 75.99% | 252.19% | 119.08% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.95% | 16.05% | 10.57% | 21.68% | |
Graham Net Nets |
(0.13) | (0.09) | (0.06) | (0.03) | |
Graham Number |
2.57 | 1.95 | 2.35 | 0.77 | |
Earnings Yield |
(15.63%) | (14.70%) | (12.07%) | (12.70%) | |
Free Cash Flow Yield |
(8.84%) | (8.71%) | (7.67%) | (8.24%) | |
Revenue per Share |
0.11 | 0.12 | 0.12 | 0.12 | |
Operating CF per Share |
(0.08) | (0.12) | (0.08) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.12) | (0.08) | (0.12) | |
Cash per Share |
0.79 | 0.90 | 1.13 | 1.17 | |
Shareholders Equity per Share |
(0.45) | (0.28) | (0.31) | (0.04) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.45) | (0.28) | (0.31) | (0.04) | |
Free Cash Flow |
(9.65) | (14.86) | (8.55) | (12.88) | |
Working Capital |
102.02 | 98.43 | 101.66 | 126.10 | |
Capital Expenditures |
(0.21) | (0.05) | (0.08) | (0.23) | |
Net Current Asset Value |
(70.20) | (45.00) | (44.82) | (15.99) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.02 | |
Net Profit Margin |
(165.45%) | (55.77%) | (244.79%) | (120.61%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.60 | 8.66 | 12.55 | 10.74 | |
Average Payables |
10.46 | 12.08 | 20.07 | 9.22 | |
Average Inventory |
7.75 | 7.63 | 6.11 | 7.45 | |
Average Assets |
112.90 | 121.68 | 130.92 | 136.76 | |
Average Common Equity |
(64.59) | (47.49) | (46.91) | (24.76) |
Columns are period end dates